Overall genomic pattern is a predictor of outcome in neuroblastoma
- PMID: 19171713
- DOI: 10.1200/JCO.2008.16.0630
Overall genomic pattern is a predictor of outcome in neuroblastoma
Abstract
Purpose: For a comprehensive overview of the genetic alterations of neuroblastoma, their association and clinical significance, we conducted a whole-genome DNA copy number analysis.
Patients and methods: A series of 493 neuroblastoma (NB) samples was investigated by array-based comparative genomic hybridization in two consecutive steps (224, then 269 patients).
Results: Genomic analysis identified several types of profiles. Tumors presenting exclusively whole-chromosome copy number variations were associated with excellent survival. No disease-related death was observed in this group. In contrast, tumors with any type of segmental chromosome alterations characterized patients with a high risk of relapse. Patients with both numerical and segmental abnormalities clearly shared the higher risk of relapse of segmental-only patients. In a multivariate analysis, taking into account the genomic profile, but also previously described individual genetic and clinical markers with prognostic significance, the presence of segmental alterations with (HR, 7.3; 95% CI, 3.7 to 14.5; P < .001) or without MYCN amplification (HR, 4.5; 95% CI, 2.4 to 8.4; P < .001) was the strongest predictor of relapse; the other significant variables were age older than 18 months (HR, 1.8; 95% CI, 1.2 to 2.8; P = .004) and stage 4 (HR, 1.8; 95% CI, 1.2 to 2.7; P = .005). Finally, within tumors showing segmental alterations, stage 4, age, MYCN amplification, 1p and 11q deletions, and 1q gain were independent predictors of decreased overall survival.
Conclusion: The analysis of the overall genomic pattern, which probably unravels particular genomic instability mechanisms rather than the analysis of individual markers, is essential to predict relapse in NB patients. It adds critical prognostic information to conventional markers and should be included in future treatment stratification.
Similar articles
-
Accumulation of segmental alterations determines progression in neuroblastoma.J Clin Oncol. 2010 Jul 1;28(19):3122-30. doi: 10.1200/JCO.2009.26.7955. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516441
-
Bladder cancer stage and outcome by array-based comparative genomic hybridization.Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012-22. doi: 10.1158/1078-0432.CCR-05-0177. Clin Cancer Res. 2005. PMID: 16203795
-
High-resolution cDNA microarray-based comparative genomic hybridization analysis in neuroblastoma.Cancer Lett. 2005 Oct 18;228(1-2):71-81. doi: 10.1016/j.canlet.2004.12.056. Cancer Lett. 2005. PMID: 15951107 Review.
-
Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.Carcinogenesis. 2004 Sep;25(9):1599-609. doi: 10.1093/carcin/bgh173. Epub 2004 Apr 16. Carcinogenesis. 2004. PMID: 15090470 Review.
-
Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M. Med Pediatr Oncol. 2001. PMID: 11464859
Cited by
-
The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches.Cancers (Basel). 2024 May 13;16(10):1863. doi: 10.3390/cancers16101863. Cancers (Basel). 2024. PMID: 38791942 Free PMC article. Review.
-
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.Cancers (Basel). 2024 Apr 29;16(9):1735. doi: 10.3390/cancers16091735. Cancers (Basel). 2024. PMID: 38730688 Free PMC article.
-
Olive Oil Components as Novel Antioxidants in Neuroblastoma Treatment: Exploring the Therapeutic Potential of Oleuropein and Hydroxytyrosol.Nutrients. 2024 Mar 13;16(6):818. doi: 10.3390/nu16060818. Nutrients. 2024. PMID: 38542729 Free PMC article. Review.
-
Neuroblastoma Patients' Outcome and Chromosomal Instability.Int J Mol Sci. 2023 Oct 24;24(21):15514. doi: 10.3390/ijms242115514. Int J Mol Sci. 2023. PMID: 37958497 Free PMC article.
-
Use of Optical Genome Mapping to Detect Structural Variants in Neuroblastoma.Cancers (Basel). 2023 Oct 31;15(21):5233. doi: 10.3390/cancers15215233. Cancers (Basel). 2023. PMID: 37958407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical